CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Multiple analysts have issued price targets for $CRSP recently. We have seen 15 analysts offer price targets for $CRSP in the last 6 months, with a median target of ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C. Wainwright reiterated a “Buy” rating on ...

CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen brokerages that are covering the firm, Marketbeat Ratings reports. One equities ...